Form 4: Lyell Immunopharma General Counsel Granted 100,000 Stock Options

Lyell Immunopharma, Inc.'s General Counsel, Mark A. Meltz, was granted 100,000 stock options with an exercise price of $12.47, vesting over four years.

Summary

• Mark A. Meltz, General Counsel of Lyell Immunopharma, Inc. (LYEL), was granted 100,000 stock options.
• The options have an exercise price of $12.47 per share.
• The transaction date for the grant was June 9, 2025.
• The options will expire on June 8, 2035.
• Following this transaction, Mr. Meltz beneficially owns 100,000 derivative securities.
• The vesting schedule for these options is 25% on June 9, 2026, with the remaining 75% vesting in equal monthly installments over the subsequent 36 months, contingent on continued service.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal as it aligns management's interests with shareholder value and and serves as a retention tool. It's a standard compensation practice.

Positives

• The grant of 100,000 stock options to General Counsel Mark A. Meltz aligns his interests with long-term shareholder value creation.
• The options have a 10-year expiration date, providing a long window for potential value realization.

Risks

• The value of the granted options is subject to the future performance of Lyell Immunopharma's common stock.
• Vesting of the options is contingent upon the reporting person's continued service to the company.

Future Outlook

The document details a standard equity compensation grant to an executive, with future vesting contingent on continued service, aligning executive incentives with long-term company performance.

Industry Context

This Form 4 filing reflects a routine executive compensation event within the biotechnology or pharmaceutical industry, where stock options are a common component of long-term incentive plans designed to retain key talent and align management interests with shareholder value.

Comparison to Industry Standards

• The grant of 100,000 stock options to a General Counsel is a common practice in the biotechnology and pharmaceutical sectors for executive compensation, aiming to incentivize long-term performance.
• The vesting schedule of 25% after one year and monthly thereafter for three years is a standard four-year vesting period, comparable to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for similar executive roles, though the specific number of options varies based on company size, executive level, and compensation philosophy.

Related Party Transactions

• The grant of 100,000 stock options to Mark A. Meltz, the General Counsel, constitutes a related party transaction as it involves compensation to an executive officer.

Stakeholder Impact

• Shareholders: The option grant aligns the General Counsel's incentives with shareholder interests, potentially leading to better long-term performance. However, it also represents potential future dilution if options are exercised.
• Employees: This grant is specific to an executive and does not directly impact the broader employee base, though it reflects the company's compensation philosophy for key personnel.

Next Steps

• The first 25% of the granted options will vest on June 9, 2026.
• The remaining options will vest in equal monthly installments over the subsequent thirty-six months.
• The reporting person must continue providing service through the applicable vesting dates to receive the shares.

Key Dates

Recommendation

Keywords

Lyell Immunopharma, LYEL, Stock Options, SEC Form 4, Insider Transaction, Executive Compensation, Mark A Meltz, General Counsel, Equity Grant, Vesting Schedule